Sigyn Therapeutics (OTCQB:SIGY) submitted a Patent Cooperation Treaty (PCT) application for the technologies it is developing to enhance the clinical benefit of chemotherapeutic drugs.
Chemotherapy is the most commonly administered drug to treat cancer, however less than 5% of administered doses reach their tumor-site target.
Sigyn’s PCT application is entitled “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity” and is associated with the company’s ChemoPrep and ChemoPure technologies.
ChemoPrep is designed to safely increase the tumor-site saturation of chemotherapeutic agents with reduced doses, while minimizing the chemoresistance associated with 90% of metastatic cancer deaths. ChemoPure is designed to extract off-target drug agents from the bloodstream to reduce chemotherapy toxicity.
